Valuation: Athersys, Inc.

Capitalization 12.34L 10.52L 10L 9L 17.07L 11Cr 17.42L 1.14Cr 44.67L 5.51Cr 46.32L 45.34L 20Cr P/E ratio 2021
-2.31x
P/E ratio 2022 -0.14x
Enterprise value 9L 8L 7L 7L 12.19L 8.2Cr 12.44L 81.52L 31.9L 3.94Cr 33.08L 32.37L 14Cr EV / Sales 2021
33.5x
EV / Sales 2022 2.59x
Free-Float
99.27%
Yield 2021 *
-
Yield 2022 -
1 month 0
Extreme 0
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
1.14
5 years 0
Extreme 0
45.5
10 years 0
Extreme 0
109.5
Change 5d. change 1-year change 3-years change Capi.($)
0.00%-99.00% - - 61
+0.80%+5.38%+43.55%+94.08% 4.92TCr
+0.13%+3.04%+107.47%+26.86% 4.68TCr
-3.00%-5.49%+138.87%+822.04% 3.44TCr
+3.83%+4.62%+2.56%-25.22% 2.33TCr
+1.01%+2.63%+94.05%-24.18% 1.88TCr
-0.69%+2.20%+47.08%-32.55% 1.73TCr
+1.99%-1.64%+94.24%+213.73% 1.59TCr
+1.86%+5.24%-2.38%+1,185.62% 1.5TCr
+1.61%-2.09%+85.62% - 1.44TCr
Average +0.75%-9.24%+67.90%+282.55% 2.35TCr
Weighted average by Cap. +0.51%+1.87%+73.57%+243.52%

Financials

2021 2022
Net sales 55.14L 46.97L 43.47L 40.93L 76.24L 51Cr 77.81L 5.1Cr 2Cr 25Cr 2.07Cr 2.03Cr 88Cr 53.25L 45.36L 41.98L 39.53L 73.63L 50Cr 75.14L 4.93Cr 1.93Cr 24Cr 2Cr 1.96Cr 85Cr
Net income -8.7Cr -7.41Cr -6.86Cr -6.46Cr -12Cr -808.73Cr -12Cr -80Cr -31Cr -388.36Cr -33Cr -32Cr -1.38TCr -7.25Cr -6.18Cr -5.72Cr -5.38Cr -10Cr -674.6Cr -10Cr -67Cr -26Cr -323.95Cr -27Cr -27Cr -1.15TCr
Net Debt -2.76Cr -2.35Cr -2.18Cr -2.05Cr -3.82Cr -257.08Cr -3.9Cr -26Cr -10Cr -123.45Cr -10Cr -10Cr -439.85Cr -4L -3L -3L -3L -5L -3.28Cr -5L -32.65L -12.77L -1.58Cr -13.25L -12.97L -5.62Cr
Logo Athersys, Inc.
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. The MultiStem clinical product is developed from a special class of stem cells called Multipotent Adult Progenitor Cells. The Company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
Employees
24
Date Price Change Volume
09/26/09 0.000001 $ 0.00% 125
08/26/08 0.000001 $ -99.00% 328
02/26/02 0.000100 $ +9,900.00% 253